Tubulin inhibitors: a patent review

Bibliography

• Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anti Cancer Agents 2005;5:65-71
   PubMedGoogle Scholar
• Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as target in oncology. Cancer Treat Rev 2009;35:255-61
   PubMed Web of Science ®Google Scholar
• Imoto Y, Yoshida Y, Yagisawa F, et al. The cell cycle, including the mitotic cycle and organelle division cycles, as revealed by cytological observations. J Electron Microsc 2011;60(S1):S117-36
   PubMedGoogle Scholar
• Nogales E, Whittaker M, Milligan RA, Downing KH. High-resolution model of the microtubule. Cell 1999;96:79-88
   PubMed Web of Science ®Google Scholar
• Amos LA. What tubulin drugs tell us about microtubule structure and dynamics. Semin Cell Dev Biol 2011;22:916-26
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:1-11
   PubMedGoogle Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335:241-8
   PubMed Web of Science ®Google Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011;37:63-74
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Baguley BC. Disrupting established tumor blood vessels. Cancer 2010;116:1859-71
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MN. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Zurwerra D, et al. Molecular mechanism of action of microtubule-satbilizing anticancer agents. Science 2013;339:587-60
   PubMed Web of Science ®Google Scholar
• Chen J-G, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and –destabilizing drugs. Cancer Res 2002;62:1935-8
   PubMed Web of Science ®Google Scholar
• Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95
   PubMed Web of Science ®Google Scholar
• Yue Q-X, Liu X, Guo D-A. Microtubule-binding natural products for cancer therapy. Planta Med 2010;76:1037-43
   PubMed Web of Science ®Google Scholar
• Kingston DGI. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-15
   PubMed Web of Science ®Google Scholar
• Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin N Am 2012;26:607-28
   PubMed Web of Science ®Google Scholar
• Cutts JH, Beer CT, Noble RL. Biological properties of vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res 1960;20:1023-31
   PubMed Web of Science ®Google Scholar
• Gupta S, Bhattacharyya B. Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 2003;253:41-7
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, TenDyke K, Towle MJ, et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 2009;8:2852-60
   PubMed Web of Science ®Google Scholar
• Sasse F, Steinmetzm H, Heil J, et al. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubule production, isolation, physic-chemical and biological properties. J Antibiot (Tokyo) 2000;53:879-85
   PubMed Web of Science ®Google Scholar
• Khalil MW, Sasse F, Lünsdorf H, et al. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. ChemBioChem 2006;7:678-83
   PubMed Web of Science ®Google Scholar
• Zeino M, Zhao Q, Eichhorn T, et al. Molecular docking studies of myxobacterial disorazoles and tubulysins to tubulin. J Biosci Med 2013;3:37-44
   Google Scholar
• Kaur G, Hollingshead M, Holbeck S, et al. Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J 2006;396:235-42
   PubMed Web of Science ®Google Scholar
• Wilson L, Meza I. The mechanism of action of colchicine. J Cell Biol 1973;58:709-19
   PubMed Web of Science ®Google Scholar
• Babttacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008;28:155-83
   PubMed Web of Science ®Google Scholar
• Uppuluri S, Knipling L, Sackett DL, Wolff J. Localization of the colchicine-binding site of tubulin. Proc Natl Acad Sci USA 1993;90:11598-602
   PubMed Web of Science ®Google Scholar
• Colchicine (marketed as Colcrys) information. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Reasearch, 2005. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm174382.htm [Last accessed 18 August 2013]
   Google Scholar
• Lu Y, Chen J, Xiao M, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943-71
   PubMed Web of Science ®Google Scholar
• Massarotti A, Coluccia A, Silvestri R, et al. The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem 2012;7:33-42
   PubMed Web of Science ®Google Scholar
• Pettit GR, Cragg GM, Herald DL, et al. Isolation and structure of combretastatin. Can J Chem 1982;60:1374-6
   Web of Science ®Google Scholar
• Pettit GR, Singh SB, Niven ML, et al. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum Caffrum. J Nat Prod 1987;50:119-31
   PubMed Web of Science ®Google Scholar
• Shen C-H, Shee J-J, Wu J-Y, et al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 2010;160:2008-27
   PubMed Web of Science ®Google Scholar
• Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical ststus. Expert Opin Investig Drugs 2004;13:1171-82
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature disabling agent combrestatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18:189-97
   PubMed Web of Science ®Google Scholar
• Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18:1541-8
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncology Biol Phys 2002;54:1491-6
   PubMed Web of Science ®Google Scholar
• Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6:395-404
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009;90:284-94
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12:4090-4
   PubMed Web of Science ®Google Scholar
• Patterson DM, Zweifel M, Middleton MR, et al. Phase I Clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012;18:1415-25
   PubMed Web of Science ®Google Scholar
• Liou J-P, Chang Y-L, Kuo F-M, et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-Aroylindoles and 3-Aroylindoles, as novel classes of potent antitubulin agents. J Med Chem 2004;47:4247-57
   PubMed Web of Science ®Google Scholar
• Kuo C-C, Hsieh H-P, Pan W-Y, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer res 2004;64:4621-8
   PubMed Web of Science ®Google Scholar
• Wang X, Wu E, Wu J, et al. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PLoS One 2013;8:e65686
   Web of Science ®Google Scholar
• Liu L, Beck H, Wang X, et al. Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. PLoS One 2012;7:e43314
   Web of Science ®Google Scholar
• Chen C-P, Hu C-B, Yeh K-C, et al. Antiangiogenic activites and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res 2010;30:2813-22
   PubMed Web of Science ®Google Scholar
• Yee KWL, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-24
   PubMed Web of Science ®Google Scholar
• Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12:2834-40
   PubMed Web of Science ®Google Scholar
• Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:1111-15
   PubMed Web of Science ®Google Scholar
• Mauer AM, Cohen EEW, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631-6
   PubMed Web of Science ®Google Scholar
• Rudin CM, Mauer A, Smakal M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2011;29:1075-82
   PubMed Web of Science ®Google Scholar
• Bacher G, Beckers T, Emig P, et al. New small-molecule tubulin inhibitors. Pure Appl Chem 2001;73:1459-64
   Web of Science ®Google Scholar
• Bacher G, Nickel B, Emig P, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001;61:392-9
   PubMed Web of Science ®Google Scholar
• Wienecke A, Bacher G. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res 2009;69:171-7
   PubMed Web of Science ®Google Scholar
• Kuppens IELM, Witteveen PO, Schot M, et al. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Invest New Drugs 2007;25:227-35
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Witteveen PO, Schwartz B, et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest New Drugs 2010;28:163-70
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
   PubMed Web of Science ®Google Scholar
• Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature 1995;375:424-7
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic—thirteenth bruce F. cain memorial award lecture. Cancer Res 1995;55:753-60
   PubMed Web of Science ®Google Scholar
• Yvon A-MC, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947-59
   PubMed Web of Science ®Google Scholar
• Amos LA, Löwe J. How Taxol® stabilizes microtubule structure. Chem Biol 1999;6:R65-9
   PubMed Web of Science ®Google Scholar
• Magnani M, Maccari G, Andreu JM, et al. Possible binding site for paclitaxel at microtubule pores. FEBS J 2009;276:2701-12
   PubMed Web of Science ®Google Scholar
• Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14:7167-72
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. Albumin-bond formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009;4:99-105
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ross H, O’Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13
   PubMed Web of Science ®Google Scholar
• Langer CJ, O’Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol 2008;3:623-30
   PubMed Web of Science ®Google Scholar
• Régina A, Demeule M, Ché C, et al. Antitumour activity of ANG 1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. Br J Pharmacol 2008;155:185-97
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gabrail N, Chandhasin C, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 2012;11:308-16
   PubMed Web of Science ®Google Scholar
• Ferron GM, Dai Y, Semiond D. Population pharmacolinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71:681-92
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Boku N, Minami H. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2009;65:129-36
   PubMed Web of Science ®Google Scholar
• Diéras V, Limentani S, Romieu G, et al. Phase II multicancer study of larotaxel (XPR9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008;19:1255-60
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33
   PubMed Web of Science ®Google Scholar
• Bode CJ, Gupta ML Jr, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2004;41:3870-4
   Web of Science ®Google Scholar
• Khrapunovich-Baine M, Menon V, Yang C-PH, et al. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem 2011;286:11765-78
   PubMed Web of Science ®Google Scholar
• Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009;8:275-81
   PubMed Web of Science ®Google Scholar
• Cortes J, Vidal M. Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 2012;133:821-30
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Mariani M, Andreoli M, et al. Novel drugs targeting microtubules: the role of epothilones. Curr Pharm Des 2012;18:2793-803
   PubMed Web of Science ®Google Scholar
• Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents- the epothilones. Biol Targets Ther 2008;2:789-811
   PubMedGoogle Scholar
• DeConti RC, Algazi AP, Andrews S, et al. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer 2010;103:1548-53
   PubMed Web of Science ®Google Scholar
• McMeekin S, Patel R, Verschraegen C, et al. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer 2012;106:70-6
   PubMed Web of Science ®Google Scholar
• Beer TM, Smith DC, Hussain A, et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the department of defense prostate cancer clinical trials consortium. Br J Cancer 2012;107:808-13
   PubMed Web of Science ®Google Scholar
• Corley DG, Herb R, Moore RE, et al. Laulimalides. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J Org Chem 1988;53:3644-6
   Web of Science ®Google Scholar
• Quinoa E, Kakou Y, Crews P. Fijianolides, polyketide heterocycles from a marine sponge. J Org Chem 1988;53:3642-4
   Web of Science ®Google Scholar
• Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999;59:653-60
   PubMed Web of Science ®Google Scholar
• Mulzer J, Öhler E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. Chem Rev 2003;103:3753-86
   PubMed Web of Science ®Google Scholar
• Pryor DE, O’Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide dose not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109-15
   PubMed Web of Science ®Google Scholar
• Pineda O, Farràs J, Maccari L, et al. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004;14:4825-9
   PubMed Web of Science ®Google Scholar
• Bennett MJ, Barakat K, Huzil JT, et al. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol 2010;17:725-34
   PubMed Web of Science ®Google Scholar
• Gapud EJ, Bai R, Ghosh AK, Hamel E. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 2004;66:113-21
   PubMed Web of Science ®Google Scholar
• Liu J, Towle MJ, Cheng H, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-18
   PubMed Web of Science ®Google Scholar
• Hood KA, West LM, Rouwé B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002;62:3356-60
   PubMed Web of Science ®Google Scholar
• Gaitanos TN, Buey RM, Díaz JF, et al. Peloruside A dose not bind to the taxoid site on β-tubulin and trtains its activity in multidrug-resistant cell lines. Cancer Res 2004;64:5063-7
   PubMed Web of Science ®Google Scholar
• Nguyen TL, Xu X, Gussio R, et al. The assembly-inducing laulimalide/peloruside A binding site on tubulin: molecular modeling and biochemical studies with [3H] peloruside A. J Chem Inf Model 2010;50:2019-28
   PubMed Web of Science ®Google Scholar
• Hamel E, Day BW, Miller JH, et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-64
   PubMed Web of Science ®Google Scholar
• Chaplin JH, Gill GS, Grobelny DW, et al. inventors; Bionomics Ltd, assignee. Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerization inhibitors. US0053351A1; 2013
   Google Scholar
• Bernard Luke Flynn; inventors; Bionomics Ltd, assignee. Chemical processes for the manufacture of substituted benzofurans. WO006686A1; 2012
   Google Scholar
• Chaplin JH, Gill GS, Grobelny DW, Flynn BL; inventors; Bionomics Ltd, assignee. Novel tubulin polymerization inhibitors. US0309768A1; 2012
   Google Scholar
• Leblond B, Taverne T, Beausoleil E, et al. inventors; Exonhit S.A., assignee. Substituted isoquinolines and their use as tubulin polymerization inhibitors. WO151423A1; 2011
   Google Scholar
• Leblond B, Taverne T, Beausoleil E, et al. inventors; Exonhit S.A., assignee. Substituted isoquinolines and their use as tubulin polymerization inhibitors. US0131018A1; 2013
   Google Scholar
• Liou J-P, Chang J-Y; inventors; Taipei medical university, National health research institutes, assignee. Aroylquinoline compounds. TW201138772A1; 2011
   Google Scholar
• Dalton JT, Miller DD, Sunjoo AHN, et al. inventors. Indoles, derivatives and analogs thereof and uses therefor. US0022121A1; 2012
   Google Scholar
• Sun L, Jiang J, Borella C, et al. inventors; Synta Pharmaceuticals Corp. assignee. Compounds for the treatment of proliferative disorders. US0040937A1; 2012
   Google Scholar
• Sun L, Borella C, Li H, et al. inventors; Synta Pharmaceuticals Corp. assignee. Compounds for the treatment of proliferative disorders. US0059893A1; 2011
   Google Scholar
• Liu Z, Liu L, Han Y, et al. inventors; Institute of medicinal biotechnology Chinese academy of medical sciences, assignee. Substituted biaryl-methylene-cycloalkyl derivatives and its preparations and applications. CN102786394A; 2012
   Google Scholar
• Negi AS, Prakasham AP, Saxena AK, et al. inventors; Council of scientific and industrial research, assignee. Anticancer and tubulin polymerization inhibition activity of benzylidene indanones and process of preparing the same. US0079396A1; 2013
   Google Scholar
• Walsh JJ, Shah R, Mccormack EM, et al. inventors; The provost, fellows, foundation scholars, and the other members of board, of the college of the holy and undivided trinity of Queen Elizabeth, near Dublin, assignee. Tubulin binding agents. WO026942A1; 2013
   Google Scholar
• Nickel B, Bacher G, Klenner T, et al. inventors. Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties. US0057124A1; 2008
   Google Scholar
• Wallner BP, Schwartz BE, Marnitsky PB, et al. inventors; Ziopharm oncology, Inc., assignee. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer. WO066807A1; 2008
   Google Scholar
• Wang Y, Zhang C, Liu XR, et al. inventors; Nanjing Sanhome pharmaceutical Co., Ltd, assignee. Tumor targeting drugs C-A4 derivatives. CN102863388A; 2013
   Google Scholar
• Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents. J Med Chem 1990;33:1948-54
   PubMed Web of Science ®Google Scholar
• Boumendjel A, Boccard J, Carrupt P-A, et al. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem 2008;51:2307-10
   PubMed Web of Science ®Google Scholar
• Lin C-N, Tu H-Y, Huang A-M, et al. inventors; Kaohsiung medical university, assignee. Synthesis and biological evaluation of 2’,5’-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. TW201143765A1; 2011
   Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008-2012). Expert Opin Ther Patent 2013;23:203-13
   PubMed Web of Science ®Google Scholar
• Zhu HL, Luo Y, Qiu KM; inventors; Nanjing university, assignee. Preparation of cinnamoyl sulfonamide derivatives and the application in anticancer drugs. CN102838515A; 2012
   Google Scholar
• Freyne EJE, Mevellec LA, Vialard JE, et al. inventors; Janssen pharmaceutica NV, assignee. Quinazolinone derivatives as tubulin polymerization inhibitors. WO118384A1; 2009
   Google Scholar
• Angibaud PR, Mevellec LA, Roux B, et al. inventors; Janssen-Cilag, Janssen pharmaceutica NV, assignee. Tetrahydrophenanthridinones and tetrahydrocyclopenta quinolinones as PARP and tubulin polymerization inhibitors. US0263622A1; 2011
   Google Scholar
• Burns CJ, Wilks AF, Harte MF, et al. inventors; Cytopia research Pty Ltd, assignee. Tubulin inhibitors. US0269760A1; 2011
   Google Scholar
• Chen M-H, Chuang S-H, Chen Y-J, et al. inventors; Development center for biotechnology, assignee. Novel tubulin inhibitors and methods of using the same. WO092471A2; 2012
   Google Scholar
• Richter W; inventors; R&D Biopharmaceuticals Gmbh, assignee. Tubulin inhibitors. WO057805A1; 2011
   Google Scholar
• Richter W; inventors; R&D Biopharmaceuticals Gmbh, assignee. Tubulin inhibitors. US0252739A1; 2012
   Google Scholar
• Langenhan JM, Peters NR, Guzei IA, et al. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc Natl Acad Sci USA 2005;102:12305-10
   PubMed Web of Science ®Google Scholar
• Thorson JS, Ahmed A; inventors; Wisconsin alumni research foundation, assignee. Colchicine neoglycosides and methods for their synthesis and use. WO067039A2; 2008
   Google Scholar
• Landen JW, Lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002;62:4109-14
   PubMed Web of Science ®Google Scholar
• Joshi HC, Aneja R, Vangapandu SN; inventors; Emory universicy, assignee. 9-Aminonoscapine and its use in treating cancers, including drug-resistant cancer. WO028259A2; 2010
   Google Scholar
• Lane HA, Bachmann F; inventors; Basilea pharmaceutica AG, assignee. Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles. WO113802A1; 2012
   Google Scholar
• Pohlmann J, Bachmann F; inventors; Basilea pharmaceutica AG, assignee. Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases. US0264792A1; 2012
   Google Scholar
• Bachmann F, Burger K, Pohlmann J, et al. Abstract C229: BAL27882: a novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype. Mol Cancer Ther 2009;8(12 Suppl):C229
   Web of Science ®Google Scholar